Bausch Health Companies
Also known as: BAUSCH | Bausch Health | Bausch Health Americas, Inc. | Bausch Health, Canada Inc. | Bausch Health Companies | Bausch Health Companies, INC. | Bausch Health Ireland Limited | BAUSCH HEALTH IRELAND LIMITED | Bausch Health US, LLC | BAUSCH HEALTH US, LLC | BAUSCH LOMB IRELAND | ICN Biomedicals | ICN Pharmaceuticals | ICN Pharmaceuticals (v1) | ICN Pharmaceuticals (v2) | Medical Monitor, Valeant Pharmaceuticals | Ortho Dermatologics | Valeant | VALEANT | Valeant/Bausch & Lomb | VALEANT BERMUDA | Valeant Canada Limited | VALEANT INTL | VALEANT LUXEMBOURG | Valeant Pharmaceitucals | Valeant Pharmaceutical | Valeant Pharmaceutical NA | Valeant Pharmaceuticals | Valeant Pharmaceuticals/Bausch & Lomb Incorporated | Valeant Pharmaceuticals International, Inc. | Valeant Pharmaceuticals Luxembourg S.Ã .r.l. | Valeant Pharmaceuticals NA | Valeant Pharmaceuticals, NA | Valeant Pharmaceuticals North America LLC | VALEANT PHARM INTL | VALEANT PHARMS | VALEANT PHARMS INC | VALEANT PHARMS INTL | VALEANT PHARMS LLC | VALEANT PHARMS NORTH | Valeant Russia, LLC | Yvonne Romero
Highest phase reached
Phase 4
First clinical trial
Nov 2, 1999First marketed drug
Jun 1, 1959First NDA
Jul 21, 1961Last known activity
Dec 20, 2025
Timeline
1950s
- Jun 1, 1959
Bausch Health Companies— Founded
1960s
- Jul 21, 1961
chlordiazepoxide— NDA Organization
1990s
- Jan 1, 1994
SPI Pharmaceuticals— Acquired
- Jan 1, 1994
Viratek, Inc— Acquired
2000s
- Oct 21, 2002
Circe Biomedical— Acquired
- Apr 4, 2003
desirudin— Marketing Organization
- Apr 4, 2003
desirudin— NDA Secondary Org
- Feb 2, 2005
Xcel Pharmaceuticals— Acquired
- Oct 16, 2008
Coria Laboratories— Acquired
- Nov 14, 2008
DermTech International— Acquired
- Dec 11, 2008
Dow Pharmaceutical Sciences— Acquired
- Jul 29, 2009
Tecnofarma— Acquired
- Dec 7, 2009
Laboratoires Dr. Renaud— Acquired
2010s
- Jan 1, 2010
Biovail— Acquired
- Apr 28, 2010
Vital Science Corp— Acquired
- May 27, 2010
Aton— Acquired
- Feb 1, 2011
PharmaSwiss S.A.— Acquired
- Jul 1, 2011
Dermik Laboratories— Acquired
- Aug 19, 2011
Sanitas Group— Acquired
- Aug 30, 2011
Afexa Life Sciences, Inc.— Acquired
- Nov 21, 2011
iNova— Acquired
- Feb 6, 2012
Probiotica Laboratorios Ltda— Acquired
- Feb 13, 2012
Eyetech Pharmaceuticals— Acquired
- Apr 12, 2012
Pedinol Pharmacal— Acquired
- Dec 11, 2012
Medicis— Acquired
- Feb 1, 2013
Natur Produkt— Acquired
- Mar 20, 2013
Obagi Medical Products— Acquired
- Aug 6, 2013
Bausch & Lomb— Acquired
- Jan 23, 2014
Solta Medical— Acquired
- Feb 3, 2014
PreCision Dermatology— Acquired
- Feb 23, 2015
Dendreon— Acquired
- Apr 1, 2015
Salix— Acquired
- Jul 17, 2015
Amoun Pharmaceuticals— Acquired
- Aug 20, 2015
Sprout Pharmaceuticals— Acquired
- Sep 2, 2015
Synergetics, Inc— Acquired
- Mar 16, 2019
Synergy Pharmaceuticals— Acquired
Drugs by trial phase (207 distinct, 630 trials)
Phase 4 (20 own, 45 via acquisition)
Phase 3 (12 own, 24 via acquisition)
Phase 2 (10 own, 30 via acquisition)
Phase 1 (4 own, 41 via acquisition)
Indications
Approved for
- Alcoholism
- Angina Pectoris
- Angina, Stable
- Anxiety
- Arthritis, Rheumatoid
- Breast Neoplasms
- Candidiasis
- Colonic Neoplasms
- Duodenal Ulcer
- Endocarditis
- Epilepsies, Partial
- Epilepsy, Complex Partial
- Epilepsy, Tonic-Clonic
- Epstein-Barr Virus Infections
- Heartburn
- Herpes Genitalis
- Herpes Labialis
- Herpes Simplex
- Herpes Zoster
- Hypertension
- Hypogonadism
- Hypopigmentation
- Meningitis, Cryptococcal
- Migraine Disorders
- Myasthenia Gravis
- Osteoarthritis
- Pain
- Parkinson Disease
- Psoriasis
- Puberty, Delayed
- Pulmonary Infarction
- Seizures
- Skin Diseases
- Stomach Neoplasms
- Stomach Ulcer
- Tremor
- Urinary Tract Infections
- Vitiligo
Studied for
- Acne Vulgaris
- Acquired Immunodeficiency Syndrome
- Adenocarcinoma
- Alzheimer Disease
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Back Pain
- Brain Diseases
- Carcinoma
- Carcinoma, Transitional Cell
- Cataract
- Chronic Pain
- Clostridium Infections
- Colitis
- Colitis, Ulcerative
- Colonic Diseases
- Communicable Diseases
- Conjunctivitis
- Conjunctivitis, Allergic
- Conjunctivitis, Bacterial
- Constipation
- Crohn Disease
- Depression
- Depressive Disorder
- Dermatitis
- Dermatitis, Atopic
- Diabetes Mellitus, Type 2
- Diarrhea
- DiGeorge Syndrome
- Digestive System Diseases
- Dysentery
- Eczema
- Epilepsy
- Esophagitis
- Esophagitis, Peptic
- Eye Pain
- Fever
- Fibromyalgia
- Fibrosis
- Gastroesophageal Reflux
- Gastrointestinal Diseases
- Gastrointestinal Hemorrhage
- Gastroparesis
- Glaucoma
- Hemangioma
- Hemangioma, Capillary
- Hemorrhage
- Hemorrhagic Fever, Crimean
- Hemorrhagic Fevers, Viral
- Hepatic Encephalopathy
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hernia
- Hernia, Ventral
- Hidradenitis
- Hidradenitis Suppurativa
- HIV Enteropathy
- HIV Infections
- HIV Seropositivity
- Hypersensitivity
- Hypertension
- Ileus
- Immune System Diseases
- Immunologic Deficiency Syndromes
- Infections
- Inflammation
- Inflammatory Bowel Diseases
- Intestinal Diseases
- Irritable Bowel Syndrome
- Keratosis
- Keratosis, Actinic
- Lassa Fever
- Lennox Gastaut Syndrome
- Lentivirus Infections
- Liver Cirrhosis
- Liver Diseases
- Low Back Pain
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Macular Degeneration
- Macular Edema
- Major Depressive Disorder
- Mental Disorders
- Multiple Sclerosis
- Muscle Spasticity
- Myofascial Pain Syndromes
- Nausea
- Neoplasms
- Neuralgia
- Neuralgia, Postherpetic
- Obesity
- Ocular Hypertension
- Onychomycosis
Marketed drugs (132)
Subsidiaries (32 direct, 64 total across the full acquisition tree)
- Afexa Life Sciences, Inc.
- Amoun Pharmaceuticals
- Aton
- Bausch & Lomb
- Biovail
- Circe Biomedical
- Coria Laboratories
- Dendreon
- Dermik Laboratories
- DermTech International
- Dow Pharmaceutical Sciences
- Eyetech Pharmaceuticals
- iNova
- Laboratoires Dr. Renaud
- Medicis
- Natur Produkt
- Obagi Medical Products
- Pedinol Pharmacal
- PharmaSwiss S.A.
- PreCision Dermatology
- Probiotica Laboratorios Ltda
- Salix
- Sanitas Group
- Solta Medical
- SPI Pharmaceuticals
- Sprout Pharmaceuticals
- Synergetics, Inc
- Synergy Pharmaceuticals
- Tecnofarma
- Viratek, Inc
- Vital Science Corp
- Xcel Pharmaceuticals
- Acerus Pharmaceuticals Corporation L2
- Callisto Pharmaceuticals L2
- Cambridge Laboratories, Ltd. L2
- Cosmo Pharmaceuticals L2
- DJ Pharma L2
- eyeonics, Inc. L2
- Fuisz Technologies, Ltd. L2
- GenDerm L2
- Graceway L2
- ISTA Pharmaceuticals L2
- LipoSonix L2
- Oceana Therapeutics L2
- Paul B Elder Company L2
- Pharmafair L2
- Pharma Pass, Inc L2
- Pitman-Moore L2
- Prestwick Pharmaceuticals L2
- Rohm & Haas L2
- Santarus L2
- Santhera L2
- Solano Clinical Research L2
- Sterimedix Ltd L2
- Technolas Perfect Vision L2
- Triax L2
- Ucyclyd L2
- 3M L3
- BioXell L3
- Graffinity AG L3
- Juvantia Pharma Ltd L3
- Myocontract AG L3
- Serenity Pharmaceuticals, Inc. L3
- Warren Teed L3
Recent trials (50)
- NCT07285785Lead sponsorPhase 4Dec 20, 2025
- NCT06718686CollaboratorPhase 1/Phase 2Dec 31, 2024
- NCT06673329CollaboratorPhase 1Nov 30, 2024
- NCT06809166CollaboratorPhase 4Jul 4, 2024
- NCT06312683CollaboratorPhase 4Jul 1, 2024
- NCT05976802Lead sponsorPhase 4Jun 30, 2024
- NCT05976802Study directorPhase 4Jun 30, 2024
- NCT05582434CollaboratorEarly Phase 1Jan 31, 2023
- NCT05608499CollaboratorPhase 3Oct 4, 2022
- NCT05297448Study directorPhase 3Aug 3, 2022
- NCT05297448Lead sponsorPhase 3Aug 3, 2022
- NCT05098028Lead sponsorPhase 2Nov 30, 2021
- NCT05098028Study directorPhase 2Nov 30, 2021
- NCT05071716Lead sponsorPhase 3Oct 31, 2021
- NCT05071716Study directorPhase 3Oct 31, 2021
Details
- Founded
- Costa Mesa, CA, US Jun 1, 1959
- First NDA
- Jul 21, 1961
- Last known activity
- Dec 20, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
Notes
ICN renamed Valeant in 2003 Changed name from Valeant to Bausch Health in May, 2018 --- Pre-folding founded info: 2003-01-01 Montreal Quebec CA https://en.wikipedia.org/wiki/Valeant_Pharmaceuticals ---